

FORM PTO-1449 (Modified)		Attorney Docket No.: 019904-000210US		Application No.: 09/244,457	
LIST OF PATENTS AND PUBLICATIONS FOR APPLICANT'S INFORMATION DISCLOSURE STATEMENT (Use several sheets if necessary)		Applicant: Schatzberg and Belanoff			
		Filing Date: 02/04/99		Group: 1614	
Reference Designation		U.S. PATENT DOCUMENTS			Page 1
Examiner Initial	Document No.	Date	Name	Class	Filing Date (If Appropriate)
FOREIGN PATENT DOCUMENTS					
	Document No.	Date	Country	Class	Translation (Yes/No)
WJ	AA	WO 9322685	11/11/1993	PCT	
	AB	WO 9408588	04/28/1994	PCT	No
	AC	EP 0763541	03/19/1997	EP	Yes
	AD	WO 9710827	03/27/1997	PCT	No
	AE	WO 9737664	10/16/1997	PCT	
	AF	WO 9826783	06/25/1998	PCT	No
✓	AG	WO 9826785	06/25/1998	PCT	No
OTHER ART (Including Author, Title, Date, Pertinent Pages, Etc.)					
WJ	AH	Beck C.A. et al. (1993) "The Steroid Antagonist RU486 Exerts Different Effects on the Glucocorticoid and Progesterone Receptors" Department of Pathology and Program in Molecular Biology, University of Colorado Health Sciences Center (S.K.N. D.P.E.) Vol. 123, No. 2, pp. 728-740 —			
	AI	Chrousos, G.P. et al. (1989) "Clinical Applications of RU 486, a Prototype Glucocorticoid and Progestin Antagonist." In: Baulieu, E.E. and Segal, S.J. eds. The Antiprogesterin Steroid RU 486 and Human Fertility Control. New York: Plenum Press, pp.273-284 ✓			
	AJ	F. Cadepond, Ph.D. et al., (1997) "RU486 (Mifepristone): Mechanisms of Action and Clinical Uses" Anna. Rev. Med. 1997, 48:129-56 —			
	AK	Krishnan, K.R.R. et al. (1992) "RU 486 in depression" Prog. Neuro-Psychopharmacol. & Biol. Psychiat., 16:913-920 —			
	AL	Murphy, B.E.P. et al. (1993) "Possible Use of Glucocorticoid Receptor Antagonists in the Treatment of Major Depression: Preliminary Results Using RU 486" J. Psychiatr. Neurosci., 18:209-213 —			
	AM	Murphy, B.E.P. s(1997) "Antiglucocorticoid therapies in major depression: A review" Psychoneuroendocrinology, 22:s125-132 —			
	AN	Niemán, L.K. et al. (1985) "Successful treatment of Cushing's Syndrome with the Glucocorticoid Antagonist RU 486" J. Clin. Endocrinol. Metab., 61:536-540 —			
	AO	Rothschild, A.J. et al. (1982) "The Dexamethasone Suppression Test as a Discriminator among Subtypes of Psychotic Patients" Brit. J. Psychiat., 141:471-474 —			
	AP	Rothschild, A.J. et al. (1985) "The effects of a single acute dose of dexamethasone on monoamine and metabolite levels in rat brain" Life Sci. 36:2491-2501 —			
	AQ	Sartor, O. et al. (1996) "Mifepristone: Treatment of Cushing's Syndrome" Clin. Obstetrics and Gynecol. 39:506-510 —			
	AR	Schatzberg, A.F. et al. (1983) "The Dexamethasone Suppression Test: Identification of Subtypes of Depression" Am. J. Psychiat., 140:88-91 —			
	AS	Schatzberg, A.F. et al. (1985) "A corticosteroid/dopamine hypothesis for psychotic depression and related states" J. Psychiat. Res., 19:57-64 —			
	AT	Schatzberg, A.F. et al. (1988) "The Roles of Glucocorticoid and Dopaminergic Systems in Delusional (Psychotic) Depression" Annals N.Y. Acad. of Sci., 537: 462-471 —			
	AU	Van der Lely, A.J. et al. (1991) "Rapid Reversal of Acute Psychosis in the Cushing Syndrome with the Cortisol-Receptor Antagonist Mifepristone (RU 486)" Ann. Intern. Med., 114:143-144 —			
✓	AV	Van der Lely, A.J. (1993) Pharmacy World & Science, 15:89-90			
EXAMINER		WILLIAM R. A. JARVIS		DATE CONSIDERED 3/16/00	
		PRIMARY EXAMINER			

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.